Cargando…

Near-infrared oxidative phosphorylation inhibitor integrates acute myeloid leukemia–targeted imaging and therapy

Acute myeloid leukemia (AML) is a deadly hematological malignancy with frequent disease relapse. The biggest challenge for AML therapy is the lack of methods to target and kill the heterogeneous leukemia cells, which lead to disease relapse. Here, we describe a near-infrared (NIR) fluorescent dye, I...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Chi, Liu, Tao, Luo, Peng, Gao, Li, Liao, Xingyun, Ma, Le, Jiang, Zhongyong, Liu, Dengqun, Yang, Zeyu, Jiang, Qingzhi, Wang, Yu, Tan, Xu, Luo, Shenglin, Wang, Yang, Shi, Chunmeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7775779/
https://www.ncbi.nlm.nih.gov/pubmed/33523835
http://dx.doi.org/10.1126/sciadv.abb6104
_version_ 1783630542749564928
author Zhang, Chi
Liu, Tao
Luo, Peng
Gao, Li
Liao, Xingyun
Ma, Le
Jiang, Zhongyong
Liu, Dengqun
Yang, Zeyu
Jiang, Qingzhi
Wang, Yu
Tan, Xu
Luo, Shenglin
Wang, Yang
Shi, Chunmeng
author_facet Zhang, Chi
Liu, Tao
Luo, Peng
Gao, Li
Liao, Xingyun
Ma, Le
Jiang, Zhongyong
Liu, Dengqun
Yang, Zeyu
Jiang, Qingzhi
Wang, Yu
Tan, Xu
Luo, Shenglin
Wang, Yang
Shi, Chunmeng
author_sort Zhang, Chi
collection PubMed
description Acute myeloid leukemia (AML) is a deadly hematological malignancy with frequent disease relapse. The biggest challenge for AML therapy is the lack of methods to target and kill the heterogeneous leukemia cells, which lead to disease relapse. Here, we describe a near-infrared (NIR) fluorescent dye, IR-26, which preferentially accumulates in the mitochondria of AML cells, depending on the hyperactive glycolysis of malignant cell, and simultaneously impairs oxidative phosphorylation (OXPHOS) to exert targeted therapeutic effects for AML cells. In particular, IR-26 also exhibits potential for real-time monitoring of AML cells with an in vivo flow cytometry (IVFC) system. Therefore, IR-26 represents a novel all-in-one agent for the integration of AML targeting, detection, and therapy, which may help to monitor disease progression and treatment responses, prevent unnecessary delays in administering upfront therapy, and improve therapeutic efficiency to the residual AML cells, which are responsible for disease relapse.
format Online
Article
Text
id pubmed-7775779
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher American Association for the Advancement of Science
record_format MEDLINE/PubMed
spelling pubmed-77757792021-01-14 Near-infrared oxidative phosphorylation inhibitor integrates acute myeloid leukemia–targeted imaging and therapy Zhang, Chi Liu, Tao Luo, Peng Gao, Li Liao, Xingyun Ma, Le Jiang, Zhongyong Liu, Dengqun Yang, Zeyu Jiang, Qingzhi Wang, Yu Tan, Xu Luo, Shenglin Wang, Yang Shi, Chunmeng Sci Adv Research Articles Acute myeloid leukemia (AML) is a deadly hematological malignancy with frequent disease relapse. The biggest challenge for AML therapy is the lack of methods to target and kill the heterogeneous leukemia cells, which lead to disease relapse. Here, we describe a near-infrared (NIR) fluorescent dye, IR-26, which preferentially accumulates in the mitochondria of AML cells, depending on the hyperactive glycolysis of malignant cell, and simultaneously impairs oxidative phosphorylation (OXPHOS) to exert targeted therapeutic effects for AML cells. In particular, IR-26 also exhibits potential for real-time monitoring of AML cells with an in vivo flow cytometry (IVFC) system. Therefore, IR-26 represents a novel all-in-one agent for the integration of AML targeting, detection, and therapy, which may help to monitor disease progression and treatment responses, prevent unnecessary delays in administering upfront therapy, and improve therapeutic efficiency to the residual AML cells, which are responsible for disease relapse. American Association for the Advancement of Science 2021-01-01 /pmc/articles/PMC7775779/ /pubmed/33523835 http://dx.doi.org/10.1126/sciadv.abb6104 Text en Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC). https://creativecommons.org/licenses/by-nc/4.0/ https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial license (https://creativecommons.org/licenses/by-nc/4.0/) , which permits use, distribution, and reproduction in any medium, so long as the resultant use is not for commercial advantage and provided the original work is properly cited.
spellingShingle Research Articles
Zhang, Chi
Liu, Tao
Luo, Peng
Gao, Li
Liao, Xingyun
Ma, Le
Jiang, Zhongyong
Liu, Dengqun
Yang, Zeyu
Jiang, Qingzhi
Wang, Yu
Tan, Xu
Luo, Shenglin
Wang, Yang
Shi, Chunmeng
Near-infrared oxidative phosphorylation inhibitor integrates acute myeloid leukemia–targeted imaging and therapy
title Near-infrared oxidative phosphorylation inhibitor integrates acute myeloid leukemia–targeted imaging and therapy
title_full Near-infrared oxidative phosphorylation inhibitor integrates acute myeloid leukemia–targeted imaging and therapy
title_fullStr Near-infrared oxidative phosphorylation inhibitor integrates acute myeloid leukemia–targeted imaging and therapy
title_full_unstemmed Near-infrared oxidative phosphorylation inhibitor integrates acute myeloid leukemia–targeted imaging and therapy
title_short Near-infrared oxidative phosphorylation inhibitor integrates acute myeloid leukemia–targeted imaging and therapy
title_sort near-infrared oxidative phosphorylation inhibitor integrates acute myeloid leukemia–targeted imaging and therapy
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7775779/
https://www.ncbi.nlm.nih.gov/pubmed/33523835
http://dx.doi.org/10.1126/sciadv.abb6104
work_keys_str_mv AT zhangchi nearinfraredoxidativephosphorylationinhibitorintegratesacutemyeloidleukemiatargetedimagingandtherapy
AT liutao nearinfraredoxidativephosphorylationinhibitorintegratesacutemyeloidleukemiatargetedimagingandtherapy
AT luopeng nearinfraredoxidativephosphorylationinhibitorintegratesacutemyeloidleukemiatargetedimagingandtherapy
AT gaoli nearinfraredoxidativephosphorylationinhibitorintegratesacutemyeloidleukemiatargetedimagingandtherapy
AT liaoxingyun nearinfraredoxidativephosphorylationinhibitorintegratesacutemyeloidleukemiatargetedimagingandtherapy
AT male nearinfraredoxidativephosphorylationinhibitorintegratesacutemyeloidleukemiatargetedimagingandtherapy
AT jiangzhongyong nearinfraredoxidativephosphorylationinhibitorintegratesacutemyeloidleukemiatargetedimagingandtherapy
AT liudengqun nearinfraredoxidativephosphorylationinhibitorintegratesacutemyeloidleukemiatargetedimagingandtherapy
AT yangzeyu nearinfraredoxidativephosphorylationinhibitorintegratesacutemyeloidleukemiatargetedimagingandtherapy
AT jiangqingzhi nearinfraredoxidativephosphorylationinhibitorintegratesacutemyeloidleukemiatargetedimagingandtherapy
AT wangyu nearinfraredoxidativephosphorylationinhibitorintegratesacutemyeloidleukemiatargetedimagingandtherapy
AT tanxu nearinfraredoxidativephosphorylationinhibitorintegratesacutemyeloidleukemiatargetedimagingandtherapy
AT luoshenglin nearinfraredoxidativephosphorylationinhibitorintegratesacutemyeloidleukemiatargetedimagingandtherapy
AT wangyang nearinfraredoxidativephosphorylationinhibitorintegratesacutemyeloidleukemiatargetedimagingandtherapy
AT shichunmeng nearinfraredoxidativephosphorylationinhibitorintegratesacutemyeloidleukemiatargetedimagingandtherapy